Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.
The collaboration between the trial tech company and heathcare firm is aimed at increasing study access at MinuteClinic locations using Medable’s software.
After 30 years’ experience, including stints advising top pharma firms, the expert has joined a firm offering tech aimed at elevating patient ID and enrollment.
During OSP’s November 17 online event, a group of experts will offer insights, advice, and examples of solutions that put patients at the center of studies.
The University of California at Irvine and the data firm will work on solutions that help integrate health data for both clinical trials and patient care.
The National Institute on Aging has launched Outreach Pro, an online tool aimed to help connect with underrepresented populations for Alzheimer’s trials.
The clinical study network is partnering with the Wisconsin-based health system to increase the reach of trials into a largely rural patient population.
Thanks in part to swift COVID-19 response and relatively low infection rates, more sites and sponsors are looking at the region to locate their studies.
The life-sciences data outfit has chosen former FDA principal deputy commissioner Amy Abernethy to serve as president of its clinical research business.
The two tech-focused firms are joining forces to work on technology solutions aimed at improving patient recruitment and enrollment for various studies.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.
The company’s Goes Direct effort seeks to partner with local doctors and other community healthcare providers to encourage broader representation in clinical trials.
Though the utilization of biosimilars in Europe is high, a report on the practices of eight countries suggests that more can be done to foster competition and remove barriers to entry.
Patients in Southern and Eastern Europe wait on average five times as long for the same treatments as patients in Northern and Western Europe, an EFPIA report finds.